Dr Hiren Mandaliya

Dr Hiren Mandaliya

Conjoint Lecturer

School of Medicine and Public Health

Career Summary

Biography

Dr Hiren Mandaliya is a fellow of The Royal Australasian College of Physicians. Dr Mandaliya also has a special interest in cancer research.

Following attainment of his fellowship, Dr Mandaliya joined Calvary Mater Newcastle as Clinical Trial Fellow in 2018 to broaden his research experience. He has been involved in multiple Phase I, Phase II, Phase III and investigator initiated trials as an investigator. He works with leading clinicians, scientists and researchers in the field. Since 2019, he has been appointed as staff specialist medical oncologist at Calvary Mater Newcastle.

Dr Mandaliya has a broad interest in the management of malignancies such as gastrointestinal, gynaecological, genitourinary, lung, melanoma, breast and head & neck. Dr Mandaliya is a regular member of the multidisciplinary tumour board meeting at John Hunter Hospital and Calvary Mater Newcastle.

Dr Mandaliya completed his MBBS and MD (Internal Medicine) in India and came to Australia in 2009. He completed his fellowship training in Medical Oncology (FRACP) at Calvary Mater Newcastle, North West Cancer Centre (Tamworth) and Macarthur Cancer Therapy Centre. Dr Mandaliya is a recipient of prestigious 'Conquer Cancer Foundation of ASCO Merit Award 2019' for his research work.

Currently he has been involved with various research projects with scientists at Calvary Mater Newcastle, University of Newcastle and Hunter Medical Research Institute along with Hunter Cancer Research Alliance. Dr Mandaliya has a strong commitment to medical education and is affiliated as a Conjoint lecturer with the University of Newcastle. He is also an active member of Future Leaders Group of Hunter Cancer Research Alliance (HCRA).

Dr Mandaliya has conducted research projects for breast, lung, gastrointestinal and other malignancies. His research work and interests have also focused on psychosocial aspects of cancer survivors and medical students’ education. He has presented his research results at various local, national and international conferences such as ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology). Dr Mandaliya has also published his research in various peer-reviewed journals.

He is a member of Medical Oncology Group of Australia (MOGA), the Australasian Gastro-Intestinal Trials Group (AGITG), Breast Cancer Trials group, ASCO and ESMO.


Qualifications

  • Bachelor of Medicine, Bachelor of Surgery, Maharaja Sayajirao University - India

Keywords

  • Cancer
  • Cancer Research
  • Cancer outcomes
  • Education
  • Medical Oncologist
  • Medical Oncology
  • Research
  • Supervisor
  • Survivorship

Languages

  • Hindi (Fluent)
  • English (Fluent)
  • Gujarati (Fluent)

Fields of Research

Code Description Percentage
321199 Oncology and carcinogenesis not elsewhere classified 100

Awards

Prize

Year Award
2019 Conquer Cancer Foundation of ASCO Merit Award
American Society of Clinical Oncology (ASCO)
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (13 outputs)

Year Citation Altmetrics Link
2021 Travers A, Adler K, Blanchard G, Bonaventura T, Charlton J, Day F, et al., 'Business as unusual: medical oncology services adapt and deliver during COVID-19', INTERNAL MEDICINE JOURNAL, 51 673-681 (2021)
DOI 10.1111/imj.15217
Co-authors Craig Gedye
2021 Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A, 'Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers.', Pharmacol Res Perspect, 9 e00808 (2021)
DOI 10.1002/prp2.808
Co-authors Moira Graves, Nikola Bowden
2020 Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab', JOURNAL OF CLINICAL MEDICINE, 9 (2020) [C1]
DOI 10.3390/jcm9082664
Citations Web of Science - 2
Co-authors Aaron Sverdlov, Doan Ngo
2020 Moth EB, Kiely BE, Martin A, Naganathan V, Della-Fiorentina S, Honeyball F, et al., 'Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences', JOURNAL OF GERIATRIC ONCOLOGY, 11 626-632 (2020)
DOI 10.1016/j.jgo.2019.07.026
Citations Scopus - 3Web of Science - 3
2019 Mandaliya H, Jones M, Oldmeadow C, Nordman IIC, 'Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)', Translational Lung Cancer Research, 8 886-894 (2019) [C1]

Background: Currently, there is no single validated biomarker which can prognosticate survival in patients with stage IV non-small cell lung cancer (NSCLC). This study examines th... [more]

Background: Currently, there is no single validated biomarker which can prognosticate survival in patients with stage IV non-small cell lung cancer (NSCLC). This study examines the prognostic significance of four biomarkers: neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) in patients with stage IV NSCLC. Methods: This study aimed to establish the relationship between NLR, LMR, PLR, ALI and overall survival (OS) at baseline and post first cycle of treatment using Cox univariate PH models. We also studied these biomarkers in the elderly (age =70 years). Clinical data was sourced from Calvary Mater Newcastle between 2010 and 2015. Results: Baseline NLR, PLR, LMR and ALI showed strong association with OS. Five unit increase in NLR and PLR was associated with an 11% and 0.5% increase in the hazard of death respectively while 1 unit increase in ALI resulted in 4% increase in hazard of death. Five unit increase in LMR was associated with a 50% reduction in hazard of death. Post-treatment NLR and low ALI correlated with shorter OS but no statistically significant relationship could be demonstrated for PLR nor LMR. Similar prognostic trends were noted for elderly. Conclusions: High NLR, high PLR, low LMR and low ALI at baseline are significantly associated with poor OS. High NLR and low ALI are significantly associated with poor OS post treatment. Findings are similar regardless of age.

DOI 10.21037/tlcr.2019.11.16
Citations Scopus - 30Web of Science - 32
Co-authors Mark Jones, Christopher Oldmeadow
2017 George M, Mandaliya H, Prawira A, 'A survey of medical oncology training in Australian medical schools: Pilot study', JMIR Medical Education, 3 (2017)

Background: Oncology is a rapidly evolving field with continuous advancements in the diagnosis and treatment of cancer. Therefore, it is important that medical students are provid... [more]

Background: Oncology is a rapidly evolving field with continuous advancements in the diagnosis and treatment of cancer. Therefore, it is important that medical students are provided with the knowledge and experience required to care for oncology patients and enable them to diagnose and manage toxicities of novel therapeutic agents. Objective: This study was performed to understand the medical students' perspective of the oncology education provided in universities across Australia and identify areas of education that could potentially be modified or improved to ultimately attract more students to a career in oncology. Methods: This pilot cross-sectional study consisted of an 18-question survey that was submitted online to medical students in their final year and interns rotating to the Tamworth Hospital. Results: The survey was completed by 94 fifth-year medical students and interns. Oncology was taught both theoretically and clinically for 68% (63/93) of participants, and 48% (44/92) had an exclusive oncology rotation. Both theoretical and clinical oncology assessments were conducted for only 21% (19/92) of participants. Overall, 42% (38/91) of participants were satisfied with their oncology education, and 78% (40/51) were dissatisfied with the number of oncology teaching hours. The importance of a career in oncology was rated as low by 46% (41/90) of participants. Conclusions: This pilot study indicates that there are potential areas to improve oncology teaching in Australian universities. The majority of surveyed students were dissatisfied with the number of teaching hours they receive in oncology. More global assessment of students and/or interns from other Australian institutes may yield further useful information.

DOI 10.2196/mededu.7903
Citations Scopus - 3
2016 Mandaliya H, Singh N, George S, George M, 'Choroid Melanoma Metastasis to Spine: A Rare Case Report.', Case Rep Ophthalmol Med, 2016 2732105 (2016)
DOI 10.1155/2016/2732105
Citations Web of Science - 2
2016 Mandaliya H, Nordman I, 'Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment', Case Reports in Oncology, 9 454-456 (2016)

The successful treatment of the rare malignancy eccrine porocarcinoma (EP) is extremely challenging, often not rewarding and when associated with metastatic disease, therapy resul... [more]

The successful treatment of the rare malignancy eccrine porocarcinoma (EP) is extremely challenging, often not rewarding and when associated with metastatic disease, therapy results are disappointing. We present a unique case of treatment response of metastatic EP, with a significant disease-free interval. The patient has remained in clinical and radiological remission for 36 months since diagnosis of metastatic disease.

DOI 10.1159/000448073
Citations Scopus - 8Web of Science - 11
2016 Mandaliya H, Ansari Z, Evans T, Oldmeadow C, George M, 'Psychosocial analysis of cancer survivors in rural Australia: Focus on demographics, quality of life and financial domains', Asian Pacific Journal of Cancer Prevention, 17 2459-2464 (2016) [C1]

Background: Cancer treatments can have long-term physical, psychological, financial, sexual and cognitive effects that may influence the quality of life. These can vary from urban... [more]

Background: Cancer treatments can have long-term physical, psychological, financial, sexual and cognitive effects that may influence the quality of life. These can vary from urban to rural areas, survival period and according to the type of cancer. We here aimed to describe demographics and psychosocial analysis of cancer survivors three to five years post-treatment in rural Australia and also assess relationships with financial stress and quality of life domains. Materials and Methods: In this cross-sectional study, 65 participants visiting the outpatient oncology clinic were given a self-administered questionnaire. The inclusion criteria included three to five years post-treatment. Three domains were investigated using standardised and validated tools such as the Standard Quality of Life in Adult Cancer Survivors Scale (QLACS) and the Personal and Household Finances (HILDA) survey. Included were demographic parameters, quality of life, treatment information and well-being. Results: There was no evidence of associations between any demographic variable and either financial stress or cancer-specific quality of life domains. Financial stress was however significantly associated with the cancerspecific quality of life domains of appearance-related concerns, family related distress, and distress related to recurrence. Conclusions: This unique study effectively points to psychosocial aspects of cancer survivors in rural regions of Australia. Although the majority of demographic characteristics were not been found to be associated with financial stress, this latter itself is significantly associated with distress related to family and cancer recurrence. This finding may be of assistance in future studies and also considering plans to fulfil unmet needs.

DOI 10.7314/APJCP.2016.17.5.2459
Citations Scopus - 7
Co-authors Christopher Oldmeadow
2015 Mandaliya H, Sung J, Hill J, Samali R, George M, 'Prostate Cancer: Cases of Rare Presentation and Rare Metastasis.', Case Rep Oncol, 8 526-529 (2015)
DOI 10.1159/000442045
Citations Scopus - 4
2015 Mandaliya H, Baghi P, Prawira A, George MK, 'A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis.', Case Rep Oncol Med, 2015 825603 (2015)
DOI 10.1155/2015/825603
Citations Web of Science - 8
2008 Prakash S, Chavda BV, Mandalia H, Dhawan R, Padmanabhan D, 'Headaches related to triptans therapy in patients of migrainous vertigo', The Journal of Headache and Pain, 9 185-188 (2008)
DOI 10.1007/s10194-008-0035-9
George M, Mandaliya H, Prawira A, 'A Survey of Medical Oncology Training in Australian Medical Schools: Pilot Study (Preprint)
DOI 10.2196/preprints.7903
Show 10 more journal articles

Conference (20 outputs)

Year Citation Altmetrics Link
2020 Williams T, Ngo DTM, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors associated with adverse cardiovascular events in cancer patients treated with Bevacizumab', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Co-authors Aaron Sverdlov, Doan Ngo
2020 Mallesara G, Kumar M, Nordman I, Mandaliya H, Ludbrook J, Day F, et al., 'Supervised exercise program in lung cancer patients on curative intent chemoradiation', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Co-authors Craig Gedye
2020 Navani V, Graves M, Marchett G, Mandaliya H, Bowden N, Van Der Westhuizen A, 'Real world exposure survival relationship of pembrolizumab in metastatic melanoma', Washington DC (virtual) (2020)
Co-authors Nikola Bowden
2020 Blanchard G, Bonaventura A, Dafters N, Day F, Gedye C, Gildenhuys J, et al., 'The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.', JOURNAL OF CLINICAL ONCOLOGY, ELECTR NETWORK (2020)
Co-authors Craig Gedye
2019 Van Der Westhuizen A, Vilain R, Graves M, Mandaliya H, Cornall K, Levy R, et al., 'PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy', Salt Lake City, UT, USA (2019)
Co-authors Moira Graves, Nikola Bowden
2019 Wilkinson KJ, Kang S, Lim SH-S, Lee CS, Asghari R, Chua W, et al., 'Patterns of adjuvant therapy use and survival outcomes in patients with rectal cancer not receiving neoadjuvant therapy in an Australian cohort.', JOURNAL OF CLINICAL ONCOLOGY, San Francisco, CA (2019)
DOI 10.1200/JCO.2019.37.4_suppl.675
2019 Kang S, Wilkinson KJ, Brungs D, Chua W, Ng WL, Asghari R, et al., 'Rectal cancer treatment and outcomes in elderly patients treated with curative intent.', JOURNAL OF CLINICAL ONCOLOGY, San Francisco, CA (2019)
DOI 10.1200/JCO.2019.37.4_suppl.678
Citations Web of Science - 1
2019 Mandaliya HA, Kim S, Quah GT, Min ST, Carlton J, Faulkner J, et al., 'Mortality within 30 days of immunotherapy (checkpoint inhibitors) in metastatic cancer patients treated at Australian tertiary cancer center.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2019)
DOI 10.1200/JCO.2019.37.15_suppl.6600
Co-authors Christopher Oldmeadow
2019 McLucas M, Mandaliya H, McGrath S, Mallesara G, 'Lenvatinib in metastatic radioiodine refractory thyroid cancer - A single centre experience', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
2019 Syed S, Lombard J, Mandaliya H, Nahar P, Ius Y, O'Sullivan R, et al., 'Axin2 Marks the Cell of Origin for Endometrial Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Co-authors Pradeep Tanwar, Shafiq Syed
2018 Maloney S, Wilkinson K, Mandaliya H, Lim S, Roohullah A, Tognela A, et al., 'Changes in colorectal cancer (CRC) presentation over a 10 year period (2005-2016) in South Western Sydney Local Health District (SWSLHD): Results from a clinicopathological database', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
2017 Mandaliya H, Mani A, George M, 'Triple Negative Breast Cancer: A Regional Australian Cancer Center Experience', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
2017 Mandaliya H, Jones M, Oldmeadow C, Nordman I, 'Prognostic importance of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR) and advanced lung cancer inflammation index (ALI) at diagnosis and post treatment in elderly with stage IV NSCLC', ANNALS OF ONCOLOGY, Singapore, SINGAPORE (2017)
Citations Scopus - 1
Co-authors Christopher Oldmeadow
2017 Mandaliya HA, Martin J, Majid A, Gani J, Sridharan S, Ackland SP, et al., 'Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2017)
DOI 10.1200/JCO.2017.35.4_suppl.499
Co-authors Michael Fay, Stephen Ackland, Jonathan Gani
2017 Kumari N, Mandaliya HA, Evans T, McElduff P, Oldmeadow C, Day FL, 'Aspirin in the prevention of colorectal cancer recurrence.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2017)
DOI 10.1200/JCO.2017.35.4_suppl.578
Co-authors Christopher Oldmeadow, Patrick Mcelduff
2017 Mandaliya H, Jones M, Oldmeadow C, Nordman I, 'Prognostic significance of advanced lung cancer inflammation index (ALI) In untreated and treated stage IV non-small cell lung cancer (NSCLC): An Australian cancer centre experience', ANNALS OF ONCOLOGY, Geneva, SWITZERLAND (2017)
Co-authors Christopher Oldmeadow
2016 Mandaliya H, George M, 'BREAST CANCER AMONG INDIGENOUS: DEMOGRAPHICS AND SURVIVAL DATA AT REGIONAL AUSTRALIAN CANCER CENTRE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
2016 Mandaliya H, George M, 'LUMINAL A BREAST CANCER: AUSTRALIAN REGIONAL CANCER CENTER EXPERIENCE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
2016 Mandaliya HA, Oldmeadow C, Evans T, Troke P, George M, 'Breast cancer demographics, screening and survival outcome at a regional Australian cancer centre: a retrospective study', ANNALS OF ONCOLOGY (2016)
DOI 10.1093/annonc/mdw387.22
Citations Scopus - 1
Co-authors Christopher Oldmeadow
2015 Mandaliya H, George M, 'A SURVEY OF MEDICAL STUDENTS' UNDERSTANDING AND ATTITUDE TOWARDS MEDICAL ONCOLOGY: A PILOT STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015)
Show 17 more conferences
Edit

Grants and Funding

Summary

Number of grants 12
Total funding $407,867

Click on a grant title below to expand the full details for that specific grant.


20212 grants / $189,815

Cardio-Oncology Strategic Initiate Grant$100,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Scheme Strategic Initiative Grant
Role Investigator
Funding Start 2021
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

Cancer Neuroscience: Defining the Landscape of Human Tumour Innervation $89,815

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Scheme Strategic Initiative Grant
Role Investigator
Funding Start 2021
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

20193 grants / $90,000

AdapTax: Feasibility, acceptibility and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer$50,000

Funding body: The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Funding body The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Scheme ANZUP Below The Belt Pedalthon Fund Clinical Trial Seed Grant
Role Investigator
Funding Start 2019
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

A blood test for human endometrial cancer$40,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Scheme HCRA Biomarkers and Targeted Therapies Flagship Program 2019
Role Investigator
Funding Start 2019
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

Publication Support Grant$0

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Scheme Publication Grant
Role Lead
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

20183 grants / $109,252

EnzaAdapt: Feasibilty, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer$50,000

Funding body: The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Funding body The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Scheme ANZUP Below The Belt Pedalthon Fund Clinical Trial Seed Grant
Role Investigator
Funding Start 2018
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

New platinum agents for the treatment of ovarian cancer research in Medical Oncology$39,252

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Scheme Calvary Mater Newcastle Hope 4 Cure Fund
Role Investigator
Funding Start 2018
Funding Finish 2021
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

Hormonal control of ovarian cancer$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Pradeep Tanwar, Ms Janine Lombard, Doctor Hiren Mandaliya, Doctor Manish Kumar Jhamb, Doctor Muhammad Fairuz Jamaluddin
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1801351
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20171 grants / $2,800

Travel Grant$2,800

Funding body: European Lung Cancer Conference

Funding body European Lung Cancer Conference
Scheme Travel Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding C3212 - International Not for profit
Category 3212
UON N

20163 grants / $16,000

Statistical Support Grant$10,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Scheme Statistical support
Role Lead
Funding Start 2016
Funding Finish 2019
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

Travel Grant$3,000

Funding body: Clinical Oncology Society of Australia

Funding body Clinical Oncology Society of Australia
Scheme Travel Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N

Travel Grant$3,000

Funding body: Medical Oncology Group of Australia

Funding body Medical Oncology Group of Australia
Scheme Travel Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON N
Edit

Research Supervision

Number of supervisions

Completed0
Current1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2020 PhD Developing Patient-Derived Ovarian Cancer Organoids as a Model for High Throughput Drug Screening and Personalised Medicine PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
Edit

Dr Hiren Mandaliya

Position

Conjoint Lecturer
School of Medicine and Public Health
College of Health, Medicine and Wellbeing

Contact Details

Email hiren.mandaliya@newcastle.edu.au
Phone (02) 401 43571

Office

Location Calvary Mater Newcastle

,
Edit